تحميل...
Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study
Our aim was to evaluate the potential cost-effectiveness of PET/CT with FES and (89)Zr-trastuzumab compared to pathology to select first-line targeted treatment in metastatic breast cancer (MBC) patients with non-rapidly progressive disease. A previously published and validated model was extended an...
محفوظ في:
| الحاوية / القاعدة: | Oncotarget |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Impact Journals LLC
2018
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5929430/ https://ncbi.nlm.nih.gov/pubmed/29731987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24869 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|